LC-MS/MS Methods Archives - AIT BioscienceAIT Bioscience


Category Archives for LC-MS/MS Methods

AIT Bioscience Presents at 12th Annual Workshop on Recent Issues in Bioanalysis

From April 9 – April 13, 2018, Philadelphia, PA was the host city for the 12th Annual Workshop on Recent Issues in Bioanalysis (WRIB). This conference brings together representatives of small and large pharmaceutical companies, regulators from around the world and toxicology and bioanalytical providers. AIT Bioscience was fortunate to have representation from three of … read the full article » »

Other Categories: Biomarkers, Ligand Binding Assays (LBA)

Tags: , , ,

Comments Off on AIT Bioscience Presents at 12th Annual Workshop on Recent Issues in Bioanalysis


AIT Bioscience’s Solution to a Tricky Peptide

AIT Bioscience’s Solution to a Tricky Peptide Triptorelin LC-MS/MS Case Study Triptorelin is used for the treatment of estrogen-dependent conditions, certain cancers, and assisted reproduction in livestock. In the treatment of advanced prostate cancer, it is a gonadotropin-releasing hormone agonist marketed by Watson Pharmaceuticals as Trelstar and typically administered as an intramuscular injection. Sequence: pGlu-His-Trp-Ser-Tyr-DTrp-Leu-Arg-Pro-Gly-NH2 … read the full article » »

Tags: , , ,

Comments Off on AIT Bioscience’s Solution to a Tricky Peptide


Getting to know AITB – By the Numbers

AIT Bioscience offers science and technology for quality bioanalytical data, and we have the numbers to prove it.   Contact info@aitbioscience.com to learn more about how AIT Bioscience can assist you in providing bioanalytical solutions.       Share this with your colleagues.Tweet

Other Categories: Biomarkers, Ligand Binding Assays (LBA), News, Screening Assay

Tags: , , ,

Comments Off on Getting to know AITB – By the Numbers


AIT Bioscience Among Inc.’s 5000 Fastest Growing Private Companies

AIT Bioscience Named to Inc. Magazine’s 36th Annual List of America’s Fastest-Growing Private Companies—the Inc. 5000   For the 2nd Time, AIT Bioscience appears on the Inc. 5000 list, Ranking No. 2366 with Three-Year Sales Growth of 153.16%   Indianapolis, IN August 16, 2017 – Inc. magazine today ranked AIT Bioscience NO. 2366 on its … read the full article » »

Other Categories: Biomarkers, Ligand Binding Assays (LBA), News, Screening Assay

Tags: , , , , , ,

Comments Off on AIT Bioscience Among Inc.’s 5000 Fastest Growing Private Companies


American Society of Mass Spectrometry in Indy

From June 4-8, the city of Indianapolis had the privilege of playing host to nearly 6500 scientists from around the world who gathered to discuss all aspects of using mass spectrometry in a wide variety of applications. Several of our scientists were able to attend talks, workshops, and short-courses on LC-MS for antibody drug conjugates, proteins, … read the full article » »

Other Categories: Ligand Binding Assays (LBA), News

Tags: , , , , , ,

Comments Off on American Society of Mass Spectrometry in Indy


AIT Bioscience Attends Bio+Tech17 and AAPS NBC Conferences

AIT Biosciences recently attended the Bio+Tech17 Conference in Bethesda, Maryland from April 27-28, 2017 and the AAPS NBC Conference in San Diego, California from May 1-3, 2017. Below are summaries of both conferences:     Bio+Tech17 Conference   The conference is run by the MD Tech Council and seeks to bring together innovators from across the … read the full article » »

Other Categories: Ligand Binding Assays (LBA), Proteins and LC-MS/MS, Special Topics, Uncategorized

Tags: , , , , , , , , ,

Comments Off on AIT Bioscience Attends Bio+Tech17 and AAPS NBC Conferences


Bioanalytical Considerations for your Dermal Pharmaceutical Programs

Bioanalytical Considerations for your Dermal Pharmaceutical Programs Does your drug require sustained release or suffer from first pass metabolism losses?   Have you considered transdermal delivery via cream gel or patch?   How does bioanalysis differ for oral or dermal delivery?   The dermis is the largest organ of the human body and provides a … read the full article » »

Other Categories: Screening Assay, Special Topics

Tags: , , , , ,

Comments Off on Bioanalytical Considerations for your Dermal Pharmaceutical Programs


Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs

The potential of antibody drug conjugates (ADCs) to provide targeted therapies for cancers and other devastating diseases have made them popular candidates for drug development programs. However, as we discussed recently in Drug Discovery and Development, the failure of several ADCs during phase II and III trials due to limited efficacy proves more complete bioanalysis … read the full article » »

Other Categories: Biomarkers, Ligand Binding Assays (LBA), Partnerships



Comments Off on Antibody Drug Conjugate Analysis: How Partnering with a Bioanalytical CRO Can Ease Preclinical ADC Programs


Therapeutic Peptides – Toeing the Line of Small and Large Molecule Bioanalysis

By: Bo Kowalczyk, Vice President of Business Development The pharmaceutical industry is so abuzz with the potential for biologic therapeutics that we often forget about peptide therapy. Despite boasting desirable qualities – low toxicity, high specificity, and high potency – the adoption of peptides into treatments faces many hurdles (Table 1). Design strategies that improve … read the full article » »

Other Categories: Ligand Binding Assays (LBA)



Comments Off on Therapeutic Peptides – Toeing the Line of Small and Large Molecule Bioanalysis


What Level of Bioanalytical Method Validation is Right for My Early Stage Drug Development Study?

During late phase drug discovery, everyone follows well established FDA bioanalytical method validation guidelines. However, opinions vary widely about what validation is necessary for early- to mid-phase studies. We are often asked by our clients: “How robust do I need this assay to be?” “At what point can I use this data to present to … read the full article » »

Other Categories: Ligand Binding Assays (LBA), Partnerships



Comments Off on What Level of Bioanalytical Method Validation is Right for My Early Stage Drug Development Study?